Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 1 Date: 16 Nov 2021
Reviewer's report:
Du et al studied HDAC inhibitors for their therapeutic potential on malignant ascites and
identified MS275 as a potential Class I HDAC inhibitor. This is an interesting and technically
sound study.
I have the following minor points.
1.  Why did the authors use proteins with >1.5 fold change were considered for fold change
calculations (P. No. 14), while proteins with >1.3 fold change for Volcano plot analysis (Figure
4B)?
2. What was the labeling efficiency?
3. The database used for bioinformatic analysis (Table 1) should be mentioned in the
Methodology section.
4. Methodology section: “Protein quantification” para, TRAQ should be corrected to “iTRAQ”.
5. Results section: The title “MS275 influenced protein distribution by iTRAQ analysis” should
be modified e.g. “MS275 influenced protein distribution”.
Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 1 Date: 16 Nov 2021
Reviewer's report:
Du et al studied HDAC inhibitors for their therapeutic potential on malignant ascites and
identified MS275 as a potential Class I HDAC inhibitor. This is an interesting and technically
sound study.
I have the following minor points.
1.  Why did the authors use proteins with >1.5 fold change were considered for fold change
calculations (P. No. 14), while proteins with >1.3 fold change for Volcano plot analysis (Figure
4B)?
2. What was the labeling efficiency?
3. The database used for bioinformatic analysis (Table 1) should be mentioned in the
Methodology section.
4. Methodology section: “Protein quantification” para, TRAQ should be corrected to “iTRAQ”.
5. Results section: The title “MS275 influenced protein distribution by iTRAQ analysis” should
be modified e.g. “MS275 influenced protein distribution”.
Please review this paper.
user
Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 1 Date: 16 Nov 2021
Reviewer's report:
Du et al studied HDAC inhibitors for their therapeutic potential on malignant ascites and
identified MS275 as a potential Class I HDAC inhibitor. This is an interesting and technically
sound study.
I have the following minor points.
1.  Why did the authors use proteins with >1.5 fold change were considered for fold change
calculations (P. No. 14), while proteins with >1.3 fold change for Volcano plot analysis (Figure
4B)?
2. What was the labeling efficiency?
3. The database used for bioinformatic analysis (Table 1) should be mentioned in the
Methodology section.
4. Methodology section: “Protein quantification” para, TRAQ should be corrected to “iTRAQ”.
5. Results section: The title “MS275 influenced protein distribution by iTRAQ analysis” should
be modified e.g. “MS275 influenced protein distribution”.
assistant